"The US Food and Drug Administration (FDA) has approved Akorn Inc's phenylephrine hydrochloride ophthalmic solution (2.5% and 10%), the company has announced.
The alpha-1 adrenergic receptor agonist is commonly used by optometrists, ophtha"...
There have been reports of inadvertent overdosage with timolol ophthalmic solution resulting in systemic effects similar to those seen with systemic beta-adrenergic blocking agents such as dizziness, headache, shortness of breath, bradycardia, bronchospasm, and cardiac arrest. With the exception of hypotension, very limited information exists on accidental ingestion of brimonidine in adults. Symptoms of brimonidine overdose have been reported in neonates, infants, and children receiving brimonidine ophthalmic solutions as part of medical treatment of congenital glaucoma or by accidental oral ingestion [see Use In Specific Populations]. Treatment of an oral overdose includes supportive and symptomatic therapy; a patent airway should be maintained.
Reactive Airway Disease Including Asthma, COPD
COMBIGAN® is contraindicated in patients with reactive airway disease including bronchial asthma; a history of bronchial asthma; severe chronic obstructive pulmonary disease [see WARNINGS AND PRECAUTIONS].
Sinus Bradycardia, AV Block, Cardiac Failure, Cardiogenic Shock
Neonates And Infants (Under the Age of 2 Years)
COMBIGAN® is contraindicated in neonates and infants (under the age of 2 years).
Local hypersensitivity reactions have occurred following the use of different components of COMBIGAN®.
COMBIGAN® is contraindicated in patients who have exhibited a hypersensitivity reaction to any component of this medication in the past.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 11/16/2015
Additional Combigan Information
Combigan - User Reviews
Combigan User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get breaking medical news.